These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 31653838)
1. Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy. Huang L; Li Y; Du Y; Zhang Y; Wang X; Ding Y; Yang X; Meng F; Tu J; Luo L; Sun C Nat Commun; 2019 Oct; 10(1):4871. PubMed ID: 31653838 [TBL] [Abstract][Full Text] [Related]
2. Firing Up Cold Tumors. Cheng WC; Ho PC Trends Cancer; 2019 Sep; 5(9):528-530. PubMed ID: 31474357 [TBL] [Abstract][Full Text] [Related]
3. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy. Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821 [TBL] [Abstract][Full Text] [Related]
4. Nanoscale Reduced Graphene Oxide-Mediated Photothermal Therapy Together with IDO Inhibition and PD-L1 Blockade Synergistically Promote Antitumor Immunity. Yan M; Liu Y; Zhu X; Wang X; Liu L; Sun H; Wang C; Kong D; Ma G ACS Appl Mater Interfaces; 2019 Jan; 11(2):1876-1885. PubMed ID: 30582788 [TBL] [Abstract][Full Text] [Related]
5. A human programmed death-ligand 1-expressing mouse tumor model for evaluating the therapeutic efficacy of anti-human PD-L1 antibodies. Huang A; Peng D; Guo H; Ben Y; Zuo X; Wu F; Yang X; Teng F; Li Z; Qian X; Qin FX Sci Rep; 2017 Feb; 7():42687. PubMed ID: 28202921 [TBL] [Abstract][Full Text] [Related]
6. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-κB inhibitor for antitumor immunotherapy. Xiao Z; Su Z; Han S; Huang J; Lin L; Shuai X Sci Adv; 2020 Feb; 6(6):eaay7785. PubMed ID: 32076650 [TBL] [Abstract][Full Text] [Related]
7. Mild near-infrared laser-triggered photo-immunotherapy potentiates immune checkpoint blockade via an all-in-one theranostic nanoplatform. Fan Y; Zhang R; Shi J; Tian F; Zhang Y; Zhang L; Liao G; Yang M J Colloid Interface Sci; 2025 Jan; 678(Pt B):1088-1103. PubMed ID: 39276517 [TBL] [Abstract][Full Text] [Related]
9. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
10. Precision USPIO-PEG-SLe Li T; Guo L; Li J; Mu X; Liu L; Song S; Luo N; Zhang Q; Zheng B; Jin G Int J Nanomedicine; 2024; 19():1249-1272. PubMed ID: 38348177 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. Inoue S; Horiuchi Y; Setoyama Y; Takeuchi Y; Beck Y; Murakami T; Odaka A J Surg Res; 2020 Sep; 253():201-213. PubMed ID: 32380346 [TBL] [Abstract][Full Text] [Related]
12. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929 [TBL] [Abstract][Full Text] [Related]
13. Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade. Wakita D; Iwai T; Harada S; Suzuki M; Yamamoto K; Sugimoto M Anticancer Res; 2019 Apr; 39(4):1749-1760. PubMed ID: 30952714 [TBL] [Abstract][Full Text] [Related]
14. Farnesoid X Receptor Constructs an Immunosuppressive Microenvironment and Sensitizes FXR You W; Li L; Sun D; Liu X; Xia Z; Xue S; Chen B; Qin H; Ai J; Jiang H Cancer Immunol Res; 2019 Jun; 7(6):990-1000. PubMed ID: 30975694 [TBL] [Abstract][Full Text] [Related]
15. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115 [TBL] [Abstract][Full Text] [Related]
16. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. Tanegashima T; Togashi Y; Azuma K; Kawahara A; Ideguchi K; Sugiyama D; Kinoshita F; Akiba J; Kashiwagi E; Takeuchi A; Irie T; Tatsugami K; Hoshino T; Eto M; Nishikawa H Clin Cancer Res; 2019 Aug; 25(15):4808-4819. PubMed ID: 31076547 [TBL] [Abstract][Full Text] [Related]
17. GSH/pH dual response drug delivery system for photothermal enhanced gene-immunotherapy. Ma T; Li W; Ye J; Huang C; Li Y; Qiu H; Yin S Nanoscale; 2023 Nov; 15(42):16947-16958. PubMed ID: 37779508 [TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Kwa MJ; Adams S Cancer; 2018 May; 124(10):2086-2103. PubMed ID: 29424936 [TBL] [Abstract][Full Text] [Related]
19. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064 [TBL] [Abstract][Full Text] [Related]
20. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells. Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]